Interferon receptor signaling in malignancy: A network of cellular pathways defining biological outcomes

Molecular Cancer Research

Volumn 12, Issue 12, 2014, Pages 1691-1703

  Fish, Eleanor N ^a   Platanias, Leonidas C ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 8; INITIATION FACTOR; INITIATION FACTOR 4B; INITIATION FACTOR 4E; INITIATION FACTOR 4G; INTERFERON; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIPROTEIN COMPLEX; PROTEIN KINASE C; PROTEIN TYROSINE PHOSPHATASE; S6 KINASE; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING; SIGNAL PEPTIDE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; DNA BINDING; GENE ACTIVATION; HUMAN; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA TRANSLATION; TRANSACTIVATION; TRANSCRIPTION INITIATION; ANIMAL; IMMUNOLOGY; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION; VIROLOGY;

ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERONS; NEOPLASMS; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION;

EID: 84919341177     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0450     Document Type: Article

References (131)

1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90.
2. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011;8:257-64.
3. Rönnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013;25:248-53.
4. Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013;382:819-31.
5. Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011;13:249.
6. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509-19.
7. Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 2013;339:1448-53.
8. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36:503-14.
9. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-86.
10. Kotenko SV. IFN-λs. Curr Opin Immunol 2011;23:583-90.
11. Kaur S, Platanias LC. IFNb-specific signaling via a unique IFNAR1 interaction. Nat Immunol 2013;14:884-5.
12. de Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, Braniff SJ, et al. Structural basis of a unique interferon- b signaling axis mediated via the receptor IFNAR1. Nat Immunol 2013;14:901-7.
13. Pott J, Mahlakõiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al. IFN-{lambda} determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci USA 2011;108:7944-9.
14. Wong VW, Sung JJ. Diagnosis and personalized management of hepatitis B including significance of genotypes. Curr Opin Infect Dis 2012;25:570-7.
15. González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012;12:125-35.
16. Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res 2013;37:1041-5.
17. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013;10:588-98.
18. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667-79.
19. Killestein J, Polman CH. Determinants of interferon β efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011;7:221-8.
20. Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet 2012;44:1243-8.
21. Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol 2010;6:40-9.
22. Begitt A, Droescher M, Meyer T, Schmid CD, Baker M, Antunes F, et al. STAT1 cooperative DNA binding distinguishes between type-1 and type-2 interferon signaling. Nat Immunol 2014;15:168-76.
23. Sadzak I, Schiff M, Gattermeier I, Glinitzer R, Sauer I, Saalmüller A, et al. Recruitment of Stat1 to chromatin is required for interferoninduced serine phosphorylation of Stat1 transactivation domain. Proc Natl Acad Sci USA 2008;105:8944-9.
24. Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, et al. Protein kinase C-d (PKC-d) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002;277:14408-16.
25. Kaur S, Parmar S, Smith J, Katsoulidis E, Li Y, Sassano A, et al. Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp Hematol 2005;33:550-7.
26. Zhao KW, Li D, Zhao Q, Huang Y, Silverman RH, Sims PJ, et al. Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cdelta and JNK. J Biol Chem 2005;280:42707-14.
27. Yanase N, Hayashida M, Kanetaka-Naka Y, Hoshika A, Mizuguchi J. PKC-d mediates interferon-a-induced apoptosis through c-Jun NH2-terminal kinase activation. BMC Cell Biol 2012;13:7.
28. Chen J, Wu M, Zhang X, Zhang W, Zhang Z, Chen L, et al. Hepatitis B virus polymerase impairs interferon-α-induced STAT activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 2013;57:470-82.
29. Hald A, Andrés RM, Salskov-Iversen ML, Kjellerup RB, Iversen L, Johansen C. STAT1 expression and activation is increased in lesional psoriatic skin. Br J Dermatol 2013;168:302-10.
30. Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, et al. Activation of protein kinase C δ by IFN-γ. J Immunol 2003;171:267-73.
31. Kwon MJ, Yao Y, Walter MJ, Holtzman MJ, Chang CH. Role of PKCdelta in IFN-gamma-inducible CIITA gene expression. Mol Immunol 2007;44:2841-9.
32. Nair JS, DaFonseca CJ, Tjernberg A, Sun W, Darnell JE Jr,Chait BT, et al. Requirement of Ca2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-g . Proc Natl Acad Sci USA 2002;99:5971-6.
33. Choudhury GG. A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase C-ε, and MAPK in mesangial cells regulates interferon-γ-induced STAT1α transcriptional activation. J Biol Chem 2004;279:27399-409.
34. Hardy PO, Diallo TO, Matte C, Descoteaux A. Roles of phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase in the regulation of protein kinase C-alpha activation in inter-feron-gamma-stimulated macrophages. Immunology 2009;128(1 Suppl):e652-60.
35. Li N, McLaren JE, Michael DR, Clement M, Fielding CA, Ramji DP. ERKis integral to the IFN-g -mediated activation of STAT1:the expression of key genes implicated in atherosclerosis, and the uptake of modi fied lipoproteins by human macrophages. J Immunol 2010;185:3041-8.
36. Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I, et al. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 2013;38:250-62.
37. Tenoever BR, Ng SL, Chua MA, McWhirter SM, García-Sastre A, Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007;315:1274-8.
38. Nishiyama-Fujita Y, Shimizu T, Sagawa M, Uchida H, Kizaki M. The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-a in CML cell line, KT-1 cells. Leuk Res 2013;37:1150-5.
39. Chen Z, Sun X, Shen S, Zhang H, Ma X, Liu J, et al. Wedelolactone, a naturally occurring coumestan, enhances interferon-g signaling through inhibiting STAT1 protein dephosphorylation. J Biol Chem 2013;288:14417-27.
40. Yetter A, Uddin S, Krolewski JJ, Jiao H, Yi T, Platanias LC. Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J Biol Chem 1995;270:18179-82.
41. Kim JH, Choi DJ, Jeong HK, Kim J, Kim DW, Choi SY, et al. DJ-1 facilitates the interaction between STAT1 and its phosphatase, SHP-1:in brain microglia and astrocytes: A novel anti-infl ammatory function of DJ-1. Neurobiol Dis 2013;60:1-10.
42. Wu X, Guo W, Wu L, Gu Y, Gu L, Xu S, et al. Selective sequestration of STAT1 in the cytoplasm via phosphorylated SHP-2 ameliorates murine experimental colitis. J Immunol 2012;189:3497-507.
43. García-Ruiz I, Solís-Muñoz P, Gómez-Izquierdo E, Muñoz-Yagüe MT, Valverde AM, Solís-Herruzo JA. Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice. J Biol Chem 2012;287:19564-73.
44. Heinonen KM, Bourdeau A, Doody KM, Tremblay ML. Protein tyrosine phosphatases PTP-1B and TC-PTP play nonredundant roles in macrophage development and IFN-gammasignaling. Proc Natl Acad Sci USA 2009;106:9368-72.
45. Porcu M, Kleppe M, Gianfelici V, Geerdens E, DeKeersmaecker K, Tartaglia M, et al. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 2012;119:4476-9.
46. Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA 2009;106:9373-8.
47. Testoni B, Völlenkle C, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. Chromatin dynamics of gene activation and repression in response to interferon alpha (IFNa) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. J Biol Chem 2011;286:20217-27.
48. Tahk S, Liu B, Chernishof V, Wong KA, Wu H, Shuai K. Control of specificity and magnitude of NF-kappa B and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proc Natl Acad Sci USA 2007;104:11643-8.
49. Begitt A, Droescher M, Knobeloch KP, Vinkemeier U. SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFNg. Blood 2011;118:1002-7.
50. Au-Yeung N, Mandhana R, Horvath CM. Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway. JAKSTAT 2013;2:e23931.
51. Gnatovskiy L, Mita P, Levy DE. The human RVB complex is required for efficient transcription of type I interferon-stimulated genes. Mol Cell Biol 2013;33:3817-25.
52. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nature Rev Immunol 2014;14:36-49.
53. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013;13:679-92.
54. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.
55. Uddin S, Majchrzak B, Woodson J, Arunkumar P, Alsayed Y, Pine R, et al. Activation of the p38 Map kinase by type I interferons. J Biol Chem 1999;274:30127-31.
56. Zhao LJ, Hua X,He SF, Ren H, Qi ZT. Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells. Virol J 2011;8:157.
57. Li Y, Sassano A, Majchrzak B, Deb DK, Levy DE, Gaestel M, et al. Role of p38alpha Map kinase in Type I interferon signaling. J Biol Chem 2004;279:970-9.
58. Lee WH, Liu FH, Lee YL, Huang HM. Interferon-alpha induces the growth inhibition of human T-cell leukaemia line Jurkat through p38alpha and p38beta. J Biochem 2010;147:645-50.
59. Verma A, Deb DK, Sassano A, Uddin S, Varga J, Wickrema A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem 2002;277:7726-35.
60. Verma A, Deb DK, Sassano A, Kambhampati S, WickremaA, Uddin S, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol 2002;168:5984-8.
61. Matsuzawa T, Kim BH, Shenoy AR, Kamitani S, Miyake M, Macmicking JD. IFN-g elicits macrophage autophagy via the p38 MAPK signaling pathway. J Immunol 2012;189:813-8.
62. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007;81:7749-58.
63. Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J, et al. Interferonalpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol 2010;38:472-80.
64. Zorzitto J, Galligan CL, Ueng JJ, Fish EN. Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro. Cell Res 2006;16:220-9.
65. Di Filippo M, Tozzi A, Tantucci M, Arcangeli S, Chiasserini D, Ghiglieri V, et al. Interferon-b1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence. Neurobiol Dis 2013;pii:S0969-9961;00281-7.
66. Katsoulidis E, Carayol N, Woodard J, Konieczna I, Majchrzak-Kita B, Jordan A, et al. Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses. J Biol Chem 2009;284:25051-64.
67. Katsoulidis E, Sassano A, Majchrzak-Kita B, Carayol N, Yoon P, Jordan A, et al. Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. J Biol Chem 2008;283:10793-803.
68. Bhattacharya S, Qian J, Tzimas C, Baker DP, Koumenis C, Diehl JA, et al. Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J Biol Chem 2011;286:22069-76.
69. Seo JY, Kim DY, Lee YS, Ro JY. Cytokine production through PKC/ p38 signaling pathways, not through JAK/STAT1 pathway, in mast cells stimulated with IFNg. Cytokine 2009;46:51-60.
70. Valledor AF, Sánchez-Tilló E, Arpa L, Park JM, Caelles C, Lloberas J, et al. Selective roles of MAPKs during the macrophage response to IFN-gamma. J Immunol 2008;180:4523-9.
71. Katsoulidis E, Li Y, Yoon P, Sassano A, Altman J, Kannan-Thulasiraman P, Balasubramanian L, et al. Role of the p38 mitogenactivated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 2005;65:9029-37.
72. Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006;108:4170-7.
73. Chai Y, Huang HL, Hu DJ, Luo X, Tao QS, Zhang XL, et al. IL-29 and IFN-a regulate the expression of MxA, 20, 50 -OAS and PKR genes in association with the activation of Raf-MEK-ERK and PI3K-AKT signal pathways in HepG2.2.15 cells. Mol Biol Rep 2011;38:139-43.
74. Banu SK, Lee J, Stephen SD, Nithy TK, Arosh JA. Interferon tau regulates PGF2alpha release from the ovine endometrial epithelial cells via activation of novel JAK/EGFR/ERK/EGR-1 pathways. Mol Endocrinol 2010;24:2315-30.
75. Qu J, Zhao M, Teng Y, Zhang Y, Hou K, Jiang Y, et al. Interferon-a sensitizes human gastric cancer cells to TRAIL-induced apoptosis via activation of the c-CBL-dependent MAPK/ERK pathway. Cancer Biol Ther 2011;12:494-502.
76. Douglas SA, Bunn SJ. Interferon-alpha signalling in bovine adrenal chromaffin cells: Involvement of signal-transducer and activator of transcription 1 and 2, extracellular signal-regulated protein kinases 1/2 and serine 31 phosphorylation of tyrosine hydroxylase. J Neuroendocrinol 2009;21:200-7.
77. Panaretakis T, Hjortsberg L, Tamm KP, Björklund AC, Joseph B, Grandér D. Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Mol Biol Cell 2008;19:41-50.
78. Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, et al. Interferon-a Suppresses cAMP to Disarm Human Regulatory T Cells. Cancer Res 2013;73:5647-56.
79. Joshi S, Kaur S, Redig AJ, Goldsborough K, David K, Ueda T, et al. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci USA 2009;106:12097-102.
80. Joshi S, Platanias LC. Mnk kinases in cytokine signaling and regulation of cytokine responses. Biomol Concepts 2012;3:127-39.
81. Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, et al. Essential role for theMnkpathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm(MPN) precursors. J Biol Chem 2013;288:23814-22.
82. Sharma B, Joshi S, Sassano A, Majchrzak B, Kaur S, Aggarwal P, et al. Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem 2012;287:42352-60.
83. Kroczynska B, Kaur S, Katsoulidis E, Majchrzak-Kita B, Sassano A, Kozma SC, et al. Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6Kmediated signals. Mol Cell Biol 2009;29:2865-75.
84. Horiuchi M, Itoh A, Pleasure D, Itoh T. MEK-ERK signaling is involved in interferon-gamma-induced death of oligodendroglial progenitor cells. J Biol Chem 2006;281:20095-106.
85. Smyth D, McKay CM, Gulbransen BD, Phan VC, Wang A, McKay DM. Interferon-gamma signals via an ERK1/2-ARF6 pathway to promote bacterial internalization by gut epithelia. Cell Microbiol 2012;14:1257-70.
86. Roy SK, Hu J, Meng Q, Xia Y, Shapiro PS, Reddy SP, et al. MEKK1 plays a critical role in activating the transcription factor C/EBP-b-dependent gene expression in response to IFN-g . Proc Natl Acad Sci USA 2002;99:7945-50.
87. Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R, et al. Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis. J Biol Chem 2011;286:6017-26.
88. Kroczynska B, Joshi S, Eklund EA, Verma A, Kotenko SV, Fish EN, et al. Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNl signaling. J Biol Chem 2011;286:1147-56.
89. Huang X, Shen N, Bao C, Gu Y, Wu L, Chen S. Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells. Arthritis Res Ther 2008;10:R91.
90. Deng J, Qian Y, Geng L, Xie H, Wang Y, Jiang G, et al. Involvement of ERK and JNK pathways in IFN-γ-induced B7-DC expression on tumor cells. J Cancer Res Clin Oncol 2011;137:243-50.
91. Kim SJ, Qian Y, Geng L, Xie H, Wang Y, Jiang G, et al. Interferongamma promotes differentiation of neural progenitor cells via the JNK pathway. Neurochem Res 2007;32:1399-406.
92. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
93. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011;10:868-80.
94. Lekmine F, Uddin S, Sassano A, Parmar S, Brachmann SM, Majchrzak B, et al. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 2003;278:27772-80.
95. Lekmine F, Sassano A, Uddin S, Smith J, Majchrzak B, Brachmann SM, et al. Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res 2004;295:173-82.
96. Kaur S, Sassano A, Joseph AM, Majchrzak-Kita B, Eklund EA, Verma A, et al. Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol 2008;181:7316-23.
97. Kaur S, Sassano A, Dolniak B, Joshi S, Majchrzak-Kita B, Baker DP, et al. Sassano A, Dolniak B, Joshi S, Majchrzak-Kita B, Baker DP, Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci USA 2008;105:4808-13.
98. Kaur S, Lal L, Sassano A, Majchrzak-Kita B, Srikanth M, Baker DP, et al. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 2007;282:1757-68.
99. Kroczynska B, Sharma B, Eklund EA, Fish EN, Platanias LC. Regulatory effects of programmed cell death 4 (PDCD4) protein in interferon (IFN)-stimulated gene expression and generation of type I IFN responses. Mol Cell Biol 2012;32:2809-22.
100. Kaur S, Sassano A, Majchrzak-Kita B, Baker DP, Su B, Fish EN, et al. Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proc Natl Acad Sci USA 2012;109:7723-8.
101. Matsumoto A, Ichikawa T, Nakao K, Miyaaki H, Hirano K, Fujimito M, et al. Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. J Gastroenterol 2009;44:856-63.
102. Burke JD, Sonenberg N, Platanias LC, Fish EN. Antiviral effects of interferon-b are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by Coxsackievirus B3. Antivir Ther 2011;16:577-84.
103. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycinsensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008;9:1157-64.
104. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6:376-85.
105. Kohanbash G, Okada H. MicoRNAs and STAT interplay. Semin Cancer Biol 2012;22:70-5.
106. Huang Y, Lei Y, Zhang H, Hou L, Zhang M, Dayton AI. MicroRNA regulation of STAT4 protein expression: rapid and sensitive modulation of IL-12 signaling in human natural killer cells. Blood 2011;118:6793-802.
107. Dentelli P, Rosso A, Orso F, Olgasi C, Taverna D, Brizzi MF. micro-RNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol 2010;30:1562-8.
108. Li A, Song W, Qian J, Li Y, He J, Zhang Q, et al. MiR-122 modulates type I interferon expression through locking suppressor of cytokine signaling 1. Int J Biochem Cell Biol 2013;45:856-65.
109. Su C, Hou Z, Zhang C, Tian Z, Zhang J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J 2011;8:354.
110. Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X, et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS ONE 2012;7:e46082.
111. Collins AS, McCoy CE, Lloyd AT, O'Farrelly C, Stevenson NJ. miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling. PLoS ONE 2013;8:e69090.
112. Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, et al. miR-155 regulates IFN-g production in natural killer cells. Blood 2012;119:3478-85.
113. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al. Tumorsecreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012;31:3513-23.
114. Noguchi S, Yamada N, Kumazaki M, Yasui Y, Iwasaki J, Naito S, et al. ssocs7, a target gene of microRNA-145:regulates interferon- induction through STAT3 nuclear translocation in bladder cancer cells. Cell Death Dis 2013;4:e482.
115. Mycko MP, Cichalewska M, Machlanska A, Cwiklinska H, Mariasiewicz M, Selmaj KW. microRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc Natl Acad Sci USA 2012;109:E1248-57.
116. Li G, Miskimen KL, Wang Z, Xie XY, Brenzovich J, Ryan JJ, et al. STAT5 requires the N-domain for suppression of miR15/16:induction of bcl-2, and survival signaling in myeloproliferative disease. Blood 2010;115:1416-24.
117. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, et al. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer 2013;12:50.
118. Lang Q, Ling C. miR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PI3KCA. Biochem Biophys ResCommun 2012;426:247-52.
119. Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, et al. Micro-RNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 2011;30:3489-501.
120. Liu P, Wilson MJ. miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/ Erk signaling pathway and NF-kB factor in human fibrosarcoma cells. J Cell Physiol 2012;227:867-76.
121. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, et al. Deregulation of miR-100, mir-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 2012;12:369.
122. Iwaya T, Yokobori T, Nishida N, Kogo R, Sudo T, Tanaka F, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis 2012;33:2391-7.
123. Lawson SK, Dobrikova EY, Shveygert M, Gromeir M. p38a mitogenactivated protein kinase depletion and repression of signal transduction to translation machinery by miR-124 and -128 in neorons. Mol Cell Biol 2013;33:127-35.
124. Tanka T, Sugaya S, Kita K, Arai M, Kanda T, Fujii K, et al. Inhibition of cell viability by human IFN-β is mediated by microRNA-431. Int J Oncol 2012;40:1470-6.
125. Li Y, Fan X, He X, Sun H, Zou Z, Yuan H, et al. MicroRNA-466I inhibits antiviral innate immune response by targeting interferon-alpha. Cell Mol Immunol 2012;9:497-502.
126. Polioudakis D, Bhinge AA, Killion PJ, Lee BK, Abell NS, Iyer VR. A Myc-micro network promotes exit from quiescence by suppressing the interferon response and cell-cycle arrest genes. Nucleic Acids Res 2013;41:2239-54.
127. Buggele WA, Horvath CM. MicroRNA pro filing of Sendai-virus infected A549 cells identifies miR-203 as an interferon-inducible regulator of IFIT1/ISG56. J Virol 2013;87:9260-70.
128. Li Y, Xie J, Xu X, Wang J, Ao F, Wan Y, et al. MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1. Protein Cell 2013;4:130-41.
129. Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ . Nature Immunol 2011;12:861-9.
130. Steiner DF, Thomas MF, Hu JK, Yang Z, Babiarz JE, Allen CD, et al. MicroRNA-29 regulates T-box transcription factors and interferon-γ production in helper T cells. Immunity 2011;35:169-81.
131. Yamada M, Gomez JC, Chugh PE, Lowell CA, Dinauer MC, Dittmer DP, et al. Interferon-γ production by neutrophils during bacterial pneumonia in mice. Am J Respir Crit Care Med 2011;183:1391-401.